Adjust Font Increase Font Decrease Font
  • Email
  • Print
  • RSS Feed

Media Releases

Statement to Physician Payments Sunshine Act Final Rule
WASHINGTON, D.C. (February 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today: “PhRMA is currently reviewing the final regulation of the Physician Payments Sunshine Act and looks forward to seeing how CMS addressed key concerns that were previously raised. PhRMA remains committed to the principles of the Sunshine Act and continues to believe that careful implementation is essential to ensuring that Sunshine fulfills its objective of usable, transparent, and understandable sharing of information.” About PhRMA The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies...
Read more

Latest Releases

PhRMA Statement on Prescription Drug Costs
8/2/2012
Today’s report by the Generic Pharmaceutical Association (GPhA) documents one of the many benefits achieved by new medicines developed by biopharmaceutical research companies. Cost savings attributable to generic drugs represent one stage of the prescription drug lifecycle. Such savings are possible because innovator biopharmaceutical research companies – the most research-intensive sector in the U.S. economy – produce medical advances through pioneering scientific work and long-term, expensive investments. Over time, these innovative new medicines lead to generic copies that patients use at low cost for many years. Without the development of new medicines by innovator companies, there would be neither the new medicines essential to progress against diseases nor generic copies.
More
Patient Assistance Programs for HIV Get Boost from HHS Secretary Sebelius
7/23/2012
"We applaud the leadership of Secretary Sebelius in recognizing the importance of patient assistance programs for people with HIV who cannot afford their prescription medicines. PhRMA and its members will utilize the common online form for patients with HIV on its Partnership for Prescription Assistance (PPA) website which has been in existence since 2005. The common online form is another way to help accelerate access to available programs."
More
Joint Industry Statement: Internet Sales and Access to Safe Medicines
7/23/2012
More
Global pharmaceutical industry calls for broad-based cooperation to fight online sales of counterfeit medicines around the world
7/23/2012
More
Nearly 200 Medicines in Development for Mental Illnesses
7/11/2012
America’s biopharmaceutical research companies are developing 187 innovative medicines to help the nearly 60 million patients in the United States who are suffering from some form of mental illness. The medicines in development – all in either clinical trials or under review by the Food and Drug Administration – include 52 for depression, 37 for schizophrenia and 26 for anxiety disorders, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).
More
PhRMA Statement on SCOTUS Ruling
6/28/2012
“We respect the Court’s decision and recognize that there will be ongoing policy discussions about the future of health care in America, and about the impact of today’s decision on the health care law. We will work with Congress and the Administration on a bipartisan basis to address these important issues and will continue to advocate for an environment that fosters medical innovation and access to new medicines. We will also continue to work for necessary changes to the Affordable Care Act, such as the repeal of the Independent Payment Advisory Board (IPAB).”
More

Subscribe to our Email Updates